Picture

Questions?

+1-866-353-3335

SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples
In Vitro Diagnostics

PUBLISHER: Market Glass, Inc. (Formerly Global Industry Analysts, Inc.) | PRODUCT CODE: 1883775

Cover Image

PUBLISHER: Market Glass, Inc. (Formerly Global Industry Analysts, Inc.) | PRODUCT CODE: 1883775

C-Reactive Protein Testing

PUBLISHED:
PAGES: 244 Pages
DELIVERY TIME: 1-2 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
PDF & Excel (Single User License)
USD 5850
PDF & Excel (Global License to Company and its Fully-owned Subsidiaries)
USD 17550

Add to Cart

Description

Table of Contents

Global C-Reactive Protein Testing Market to Reach US$3.6 Billion by 2030

The global market for C-Reactive Protein Testing estimated at US$3.3 Billion in the year 2024, is expected to reach US$3.6 Billion by 2030, growing at a CAGR of 1.7% over the analysis period 2024-2030. Immunoturbidimetric Assay, one of the segments analyzed in the report, is expected to record a 2.2% CAGR and reach US$1.9 Billion by the end of the analysis period. Growth in the ELISA segment is estimated at 1.6% CAGR over the analysis period.

The U.S. Market is Estimated at US$863.0 Million While China is Forecast to Grow at 1.7% CAGR

The C-Reactive Protein Testing market in the U.S. is estimated at US$863.0 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$580.9 Million by the year 2030 trailing a CAGR of 1.7% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.7% and 1.3% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.0% CAGR.

Global C-Reactive Protein Testing Market - Key Trends and Drivers Summarized

Beyond Inflammation: What Can C-Reactive Protein Testing Really Tell Us?

C-reactive protein (CRP) testing is a widely used diagnostic tool designed to measure the level of CRP in the blood, a protein produced by the liver in response to inflammation. The presence of CRP is associated with a variety of conditions, from acute infections to chronic diseases and autoimmune disorders. By measuring CRP levels, healthcare providers can assess if there is an inflammation in the body, determine its severity, and monitor the effectiveness of treatment. This test is particularly valuable because it can help distinguish between bacterial infections, which typically cause a higher CRP elevation, and viral infections, alongside guiding therapy in chronic inflammatory conditions like rheumatoid arthritis and Crohn's disease.

How Is Technology Enhancing CRP Testing Accuracy and Accessibility?

The accuracy and utility of CRP testing have significantly improved with advancements in medical technology. Modern CRP tests can deliver results in a matter of minutes, allowing for rapid clinical decision-making. Point-of-care CRP testing devices, which can be used directly at the patient’s bedside or in the doctor's office, are particularly revolutionary. They eliminate the need to send samples to a lab and reduce the waiting time for results. Moreover, recent developments in microfluidics and biosensing technologies have led to the creation of even smaller, more sensitive CRP testing devices that require only a tiny blood sample, making the test less invasive and more comfortable for patients.

What Challenges Are Faced in the Implementation of CRP Testing?

Despite its benefits, the implementation of CRP testing faces certain challenges. One of the primary concerns is the potential for overuse or misuse of the test, particularly in situations where CRP levels may not provide definitive diagnostic information. Misinterpretation of CRP results can lead to unnecessary treatments, such as the inappropriate use of antibiotics for viral infections. Additionally, while point-of-care CRP testing offers convenience, ensuring the accuracy and reliability of these devices across all healthcare settings is critical but challenging. Training healthcare providers to understand and integrate CRP test results effectively into the clinical context is also essential to maximize the test's benefits and avoid potential drawbacks.

What Key Factors Are Fueling the Expansion of the CRP Testing Market?

The growth in the C-Reactive Protein testing market is driven by several factors. The rising prevalence of inflammatory diseases such as cardiovascular disorders, rheumatoid arthritis, and inflammatory bowel disease has led to an increased demand for effective diagnostic and monitoring tools like CRP testing. Growing awareness among physicians and patients about the importance of inflammation and its role in various health conditions also contributes to this trend. Additionally, the expansion of point-of-care diagnostics and the increasing availability of affordable and rapid CRP testing devices have made these tests more accessible to a broader segment of the population. As health systems continue to emphasize preventive care and early intervention, CRP testing is positioned as a valuable tool in the medical arsenal, promoting its adoption and market growth across diverse healthcare environments.

SCOPE OF STUDY:

The report analyzes the C-Reactive Protein Testing market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Disease Type (Cardiovascular Diseases, Cancer, Rheumatoid Arthritis, Inflammatory Bowel Disease, Endometriosis, Lupus, Other Disease Types); Assay Type (Immunoturbidimetric Assay, ELISA, Chemiluminescence Immunoassay, Other Assay Types); End-Use (Hospitals, Laboratories, Clinics, Other End-Uses)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 43 Featured) -

  • Abaxis, Inc.
  • Abbott Laboratories
  • Danaher Corporation
  • F. Hoffmann-La Roche AG
  • Laboratory Corporation of America Holdings (LabCorp)
  • Merck KgaA
  • Quest Diagnostics, Inc.
  • Randox Laboratories Ltd.
  • Siemens Healthineers
  • Thermo Fisher Scientific, Inc.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

Show more
Product Code: MCP11362

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Trade Shocks, Uncertainty, and the Structural Rewiring of the Global Economy
    • C-Reactive Protein Testing - Global Key Competitors Percentage Market Share in 2025 (E)
    • Impact of COVID-19 Pandemic and Looming Global Recession
    • What is C-reactive Protein (CRP)?
    • An Introduction to C-reactive Protein Testing
    • Global Market Prospects & Outlook
    • Immunoturbidimetric Assays: The Major Segment by Assay Type
    • hs-CRP Test Type Leads by Detection Range
    • Cardiovascular Diseases Emerge As the Leading Disease Type for CRP Testing, Cancer Detection to Make Strong Gains
    • Clinics & Hospitals Hold Dominant Share of CRP Testing Market
    • Developed Regions Lead, Developing Economies to Spur Market Growth
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Prominence of POC Testing Approaches for C-reactive Protein Testing Enable Faster and Accurate Results
    • CRP Testing for Ascertaining Viral Infections
    • Growing Incidence of HIV Infections and Need for Monitoring of HIV Diseases Drive CRP Testing
    • Threat of Endometriosis in Women: Significant Role of CRP Testing
    • CRP Testing: A Vital Diagnostic Tool for Cancer
    • CRP Testing Holds Potential Role in Assessing Effectiveness of Antibiotic Drugs
    • Funding Support for Extensive Research on Applications of C-reactive Protein Testing to Boost Market Growth
    • Growing Use of CRP Testing in Cardiovascular Risk Assessment Bolsters Market Growth
    • Integration of CRP Testing in Routine Check-ups Enhances Early Detection Rates
    • Research Linking Inflammation to Various Chronic Diseases Strengthens Test Demand
    • Emerging Markets Offer Significant Opportunities Due to Expanding Healthcare Systems
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Recent Past, Current & Future Analysis for Cardiovascular Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 2: World Historic Review for Cardiovascular Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 3: World 15-Year Perspective for Cardiovascular Diseases by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 5: World Historic Review for Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 6: World 15-Year Perspective for Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 7: World Recent Past, Current & Future Analysis for Rheumatoid Arthritis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 8: World Historic Review for Rheumatoid Arthritis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 9: World 15-Year Perspective for Rheumatoid Arthritis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 10: World Recent Past, Current & Future Analysis for Inflammatory Bowel Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 11: World Historic Review for Inflammatory Bowel Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 12: World 15-Year Perspective for Inflammatory Bowel Disease by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 13: World Recent Past, Current & Future Analysis for Endometriosis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 14: World Historic Review for Endometriosis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 15: World 15-Year Perspective for Endometriosis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 16: World Recent Past, Current & Future Analysis for Lupus by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 17: World Historic Review for Lupus by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 18: World 15-Year Perspective for Lupus by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 19: World Recent Past, Current & Future Analysis for Other Disease Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 20: World Historic Review for Other Disease Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 21: World 15-Year Perspective for Other Disease Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 22: World Recent Past, Current & Future Analysis for Immunoturbidimetric Assay by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 23: World Historic Review for Immunoturbidimetric Assay by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 24: World 15-Year Perspective for Immunoturbidimetric Assay by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 25: World Recent Past, Current & Future Analysis for ELISA by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 26: World Historic Review for ELISA by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 27: World 15-Year Perspective for ELISA by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 28: World Recent Past, Current & Future Analysis for Chemiluminescence Immunoassay by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 29: World Historic Review for Chemiluminescence Immunoassay by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 30: World 15-Year Perspective for Chemiluminescence Immunoassay by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 31: World Recent Past, Current & Future Analysis for Other Assay Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 32: World Historic Review for Other Assay Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 33: World 15-Year Perspective for Other Assay Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 34: World Recent Past, Current & Future Analysis for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 35: World Historic Review for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 36: World 15-Year Perspective for Hospitals by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 37: World Recent Past, Current & Future Analysis for Laboratories by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 38: World Historic Review for Laboratories by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 39: World 15-Year Perspective for Laboratories by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 40: World Recent Past, Current & Future Analysis for Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 41: World Historic Review for Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 42: World 15-Year Perspective for Clinics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 43: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 44: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 45: World 15-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 46: World C-Reactive Protein Testing Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
    • TABLE 47: World Recent Past, Current & Future Analysis for C-Reactive Protein Testing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 48: World Historic Review for C-Reactive Protein Testing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 49: World 15-Year Perspective for C-Reactive Protein Testing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • C-Reactive Protein Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 50: USA Recent Past, Current & Future Analysis for C-Reactive Protein Testing by Disease Type - Cardiovascular Diseases, Cancer, Rheumatoid Arthritis, Inflammatory Bowel Disease, Endometriosis, Lupus and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: USA Historic Review for C-Reactive Protein Testing by Disease Type - Cardiovascular Diseases, Cancer, Rheumatoid Arthritis, Inflammatory Bowel Disease, Endometriosis, Lupus and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 52: USA 15-Year Perspective for C-Reactive Protein Testing by Disease Type - Percentage Breakdown of Value Sales for Cardiovascular Diseases, Cancer, Rheumatoid Arthritis, Inflammatory Bowel Disease, Endometriosis, Lupus and Other Disease Types for the Years 2015, 2025 & 2030
    • TABLE 53: USA Recent Past, Current & Future Analysis for C-Reactive Protein Testing by Assay Type - Immunoturbidimetric Assay, ELISA, Chemiluminescence Immunoassay and Other Assay Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 54: USA Historic Review for C-Reactive Protein Testing by Assay Type - Immunoturbidimetric Assay, ELISA, Chemiluminescence Immunoassay and Other Assay Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 55: USA 15-Year Perspective for C-Reactive Protein Testing by Assay Type - Percentage Breakdown of Value Sales for Immunoturbidimetric Assay, ELISA, Chemiluminescence Immunoassay and Other Assay Types for the Years 2015, 2025 & 2030
    • TABLE 56: USA Recent Past, Current & Future Analysis for C-Reactive Protein Testing by End-Use - Hospitals, Laboratories, Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: USA Historic Review for C-Reactive Protein Testing by End-Use - Hospitals, Laboratories, Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 58: USA 15-Year Perspective for C-Reactive Protein Testing by End-Use - Percentage Breakdown of Value Sales for Hospitals, Laboratories, Clinics and Other End-Uses for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 59: Canada Recent Past, Current & Future Analysis for C-Reactive Protein Testing by Disease Type - Cardiovascular Diseases, Cancer, Rheumatoid Arthritis, Inflammatory Bowel Disease, Endometriosis, Lupus and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Canada Historic Review for C-Reactive Protein Testing by Disease Type - Cardiovascular Diseases, Cancer, Rheumatoid Arthritis, Inflammatory Bowel Disease, Endometriosis, Lupus and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 61: Canada 15-Year Perspective for C-Reactive Protein Testing by Disease Type - Percentage Breakdown of Value Sales for Cardiovascular Diseases, Cancer, Rheumatoid Arthritis, Inflammatory Bowel Disease, Endometriosis, Lupus and Other Disease Types for the Years 2015, 2025 & 2030
    • TABLE 62: Canada Recent Past, Current & Future Analysis for C-Reactive Protein Testing by Assay Type - Immunoturbidimetric Assay, ELISA, Chemiluminescence Immunoassay and Other Assay Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Canada Historic Review for C-Reactive Protein Testing by Assay Type - Immunoturbidimetric Assay, ELISA, Chemiluminescence Immunoassay and Other Assay Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 64: Canada 15-Year Perspective for C-Reactive Protein Testing by Assay Type - Percentage Breakdown of Value Sales for Immunoturbidimetric Assay, ELISA, Chemiluminescence Immunoassay and Other Assay Types for the Years 2015, 2025 & 2030
    • TABLE 65: Canada Recent Past, Current & Future Analysis for C-Reactive Protein Testing by End-Use - Hospitals, Laboratories, Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Canada Historic Review for C-Reactive Protein Testing by End-Use - Hospitals, Laboratories, Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 67: Canada 15-Year Perspective for C-Reactive Protein Testing by End-Use - Percentage Breakdown of Value Sales for Hospitals, Laboratories, Clinics and Other End-Uses for the Years 2015, 2025 & 2030
  • JAPAN
    • C-Reactive Protein Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 68: Japan Recent Past, Current & Future Analysis for C-Reactive Protein Testing by Disease Type - Cardiovascular Diseases, Cancer, Rheumatoid Arthritis, Inflammatory Bowel Disease, Endometriosis, Lupus and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Japan Historic Review for C-Reactive Protein Testing by Disease Type - Cardiovascular Diseases, Cancer, Rheumatoid Arthritis, Inflammatory Bowel Disease, Endometriosis, Lupus and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 70: Japan 15-Year Perspective for C-Reactive Protein Testing by Disease Type - Percentage Breakdown of Value Sales for Cardiovascular Diseases, Cancer, Rheumatoid Arthritis, Inflammatory Bowel Disease, Endometriosis, Lupus and Other Disease Types for the Years 2015, 2025 & 2030
    • TABLE 71: Japan Recent Past, Current & Future Analysis for C-Reactive Protein Testing by Assay Type - Immunoturbidimetric Assay, ELISA, Chemiluminescence Immunoassay and Other Assay Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Japan Historic Review for C-Reactive Protein Testing by Assay Type - Immunoturbidimetric Assay, ELISA, Chemiluminescence Immunoassay and Other Assay Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 73: Japan 15-Year Perspective for C-Reactive Protein Testing by Assay Type - Percentage Breakdown of Value Sales for Immunoturbidimetric Assay, ELISA, Chemiluminescence Immunoassay and Other Assay Types for the Years 2015, 2025 & 2030
    • TABLE 74: Japan Recent Past, Current & Future Analysis for C-Reactive Protein Testing by End-Use - Hospitals, Laboratories, Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Japan Historic Review for C-Reactive Protein Testing by End-Use - Hospitals, Laboratories, Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 76: Japan 15-Year Perspective for C-Reactive Protein Testing by End-Use - Percentage Breakdown of Value Sales for Hospitals, Laboratories, Clinics and Other End-Uses for the Years 2015, 2025 & 2030
  • CHINA
    • C-Reactive Protein Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 77: China Recent Past, Current & Future Analysis for C-Reactive Protein Testing by Disease Type - Cardiovascular Diseases, Cancer, Rheumatoid Arthritis, Inflammatory Bowel Disease, Endometriosis, Lupus and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: China Historic Review for C-Reactive Protein Testing by Disease Type - Cardiovascular Diseases, Cancer, Rheumatoid Arthritis, Inflammatory Bowel Disease, Endometriosis, Lupus and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 79: China 15-Year Perspective for C-Reactive Protein Testing by Disease Type - Percentage Breakdown of Value Sales for Cardiovascular Diseases, Cancer, Rheumatoid Arthritis, Inflammatory Bowel Disease, Endometriosis, Lupus and Other Disease Types for the Years 2015, 2025 & 2030
    • TABLE 80: China Recent Past, Current & Future Analysis for C-Reactive Protein Testing by Assay Type - Immunoturbidimetric Assay, ELISA, Chemiluminescence Immunoassay and Other Assay Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: China Historic Review for C-Reactive Protein Testing by Assay Type - Immunoturbidimetric Assay, ELISA, Chemiluminescence Immunoassay and Other Assay Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 82: China 15-Year Perspective for C-Reactive Protein Testing by Assay Type - Percentage Breakdown of Value Sales for Immunoturbidimetric Assay, ELISA, Chemiluminescence Immunoassay and Other Assay Types for the Years 2015, 2025 & 2030
    • TABLE 83: China Recent Past, Current & Future Analysis for C-Reactive Protein Testing by End-Use - Hospitals, Laboratories, Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: China Historic Review for C-Reactive Protein Testing by End-Use - Hospitals, Laboratories, Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 85: China 15-Year Perspective for C-Reactive Protein Testing by End-Use - Percentage Breakdown of Value Sales for Hospitals, Laboratories, Clinics and Other End-Uses for the Years 2015, 2025 & 2030
  • EUROPE
    • C-Reactive Protein Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 86: Europe Recent Past, Current & Future Analysis for C-Reactive Protein Testing by Disease Type - Cardiovascular Diseases, Cancer, Rheumatoid Arthritis, Inflammatory Bowel Disease, Endometriosis, Lupus and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Europe Historic Review for C-Reactive Protein Testing by Disease Type - Cardiovascular Diseases, Cancer, Rheumatoid Arthritis, Inflammatory Bowel Disease, Endometriosis, Lupus and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 88: Europe 15-Year Perspective for C-Reactive Protein Testing by Disease Type - Percentage Breakdown of Value Sales for Cardiovascular Diseases, Cancer, Rheumatoid Arthritis, Inflammatory Bowel Disease, Endometriosis, Lupus and Other Disease Types for the Years 2015, 2025 & 2030
    • TABLE 89: Europe Recent Past, Current & Future Analysis for C-Reactive Protein Testing by Assay Type - Immunoturbidimetric Assay, ELISA, Chemiluminescence Immunoassay and Other Assay Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Europe Historic Review for C-Reactive Protein Testing by Assay Type - Immunoturbidimetric Assay, ELISA, Chemiluminescence Immunoassay and Other Assay Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 91: Europe 15-Year Perspective for C-Reactive Protein Testing by Assay Type - Percentage Breakdown of Value Sales for Immunoturbidimetric Assay, ELISA, Chemiluminescence Immunoassay and Other Assay Types for the Years 2015, 2025 & 2030
    • TABLE 92: Europe Recent Past, Current & Future Analysis for C-Reactive Protein Testing by End-Use - Hospitals, Laboratories, Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Europe Historic Review for C-Reactive Protein Testing by End-Use - Hospitals, Laboratories, Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 94: Europe 15-Year Perspective for C-Reactive Protein Testing by End-Use - Percentage Breakdown of Value Sales for Hospitals, Laboratories, Clinics and Other End-Uses for the Years 2015, 2025 & 2030
    • TABLE 95: Europe Recent Past, Current & Future Analysis for C-Reactive Protein Testing by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 96: Europe Historic Review for C-Reactive Protein Testing by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 97: Europe 15-Year Perspective for C-Reactive Protein Testing by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2015, 2025 & 2030
  • FRANCE
    • C-Reactive Protein Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 98: France Recent Past, Current & Future Analysis for C-Reactive Protein Testing by Disease Type - Cardiovascular Diseases, Cancer, Rheumatoid Arthritis, Inflammatory Bowel Disease, Endometriosis, Lupus and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: France Historic Review for C-Reactive Protein Testing by Disease Type - Cardiovascular Diseases, Cancer, Rheumatoid Arthritis, Inflammatory Bowel Disease, Endometriosis, Lupus and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 100: France 15-Year Perspective for C-Reactive Protein Testing by Disease Type - Percentage Breakdown of Value Sales for Cardiovascular Diseases, Cancer, Rheumatoid Arthritis, Inflammatory Bowel Disease, Endometriosis, Lupus and Other Disease Types for the Years 2015, 2025 & 2030
    • TABLE 101: France Recent Past, Current & Future Analysis for C-Reactive Protein Testing by Assay Type - Immunoturbidimetric Assay, ELISA, Chemiluminescence Immunoassay and Other Assay Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 102: France Historic Review for C-Reactive Protein Testing by Assay Type - Immunoturbidimetric Assay, ELISA, Chemiluminescence Immunoassay and Other Assay Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 103: France 15-Year Perspective for C-Reactive Protein Testing by Assay Type - Percentage Breakdown of Value Sales for Immunoturbidimetric Assay, ELISA, Chemiluminescence Immunoassay and Other Assay Types for the Years 2015, 2025 & 2030
    • TABLE 104: France Recent Past, Current & Future Analysis for C-Reactive Protein Testing by End-Use - Hospitals, Laboratories, Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: France Historic Review for C-Reactive Protein Testing by End-Use - Hospitals, Laboratories, Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 106: France 15-Year Perspective for C-Reactive Protein Testing by End-Use - Percentage Breakdown of Value Sales for Hospitals, Laboratories, Clinics and Other End-Uses for the Years 2015, 2025 & 2030
  • GERMANY
    • C-Reactive Protein Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 107: Germany Recent Past, Current & Future Analysis for C-Reactive Protein Testing by Disease Type - Cardiovascular Diseases, Cancer, Rheumatoid Arthritis, Inflammatory Bowel Disease, Endometriosis, Lupus and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Germany Historic Review for C-Reactive Protein Testing by Disease Type - Cardiovascular Diseases, Cancer, Rheumatoid Arthritis, Inflammatory Bowel Disease, Endometriosis, Lupus and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 109: Germany 15-Year Perspective for C-Reactive Protein Testing by Disease Type - Percentage Breakdown of Value Sales for Cardiovascular Diseases, Cancer, Rheumatoid Arthritis, Inflammatory Bowel Disease, Endometriosis, Lupus and Other Disease Types for the Years 2015, 2025 & 2030
    • TABLE 110: Germany Recent Past, Current & Future Analysis for C-Reactive Protein Testing by Assay Type - Immunoturbidimetric Assay, ELISA, Chemiluminescence Immunoassay and Other Assay Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Germany Historic Review for C-Reactive Protein Testing by Assay Type - Immunoturbidimetric Assay, ELISA, Chemiluminescence Immunoassay and Other Assay Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 112: Germany 15-Year Perspective for C-Reactive Protein Testing by Assay Type - Percentage Breakdown of Value Sales for Immunoturbidimetric Assay, ELISA, Chemiluminescence Immunoassay and Other Assay Types for the Years 2015, 2025 & 2030
    • TABLE 113: Germany Recent Past, Current & Future Analysis for C-Reactive Protein Testing by End-Use - Hospitals, Laboratories, Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 114: Germany Historic Review for C-Reactive Protein Testing by End-Use - Hospitals, Laboratories, Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 115: Germany 15-Year Perspective for C-Reactive Protein Testing by End-Use - Percentage Breakdown of Value Sales for Hospitals, Laboratories, Clinics and Other End-Uses for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 116: Italy Recent Past, Current & Future Analysis for C-Reactive Protein Testing by Disease Type - Cardiovascular Diseases, Cancer, Rheumatoid Arthritis, Inflammatory Bowel Disease, Endometriosis, Lupus and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: Italy Historic Review for C-Reactive Protein Testing by Disease Type - Cardiovascular Diseases, Cancer, Rheumatoid Arthritis, Inflammatory Bowel Disease, Endometriosis, Lupus and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 118: Italy 15-Year Perspective for C-Reactive Protein Testing by Disease Type - Percentage Breakdown of Value Sales for Cardiovascular Diseases, Cancer, Rheumatoid Arthritis, Inflammatory Bowel Disease, Endometriosis, Lupus and Other Disease Types for the Years 2015, 2025 & 2030
    • TABLE 119: Italy Recent Past, Current & Future Analysis for C-Reactive Protein Testing by Assay Type - Immunoturbidimetric Assay, ELISA, Chemiluminescence Immunoassay and Other Assay Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 120: Italy Historic Review for C-Reactive Protein Testing by Assay Type - Immunoturbidimetric Assay, ELISA, Chemiluminescence Immunoassay and Other Assay Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 121: Italy 15-Year Perspective for C-Reactive Protein Testing by Assay Type - Percentage Breakdown of Value Sales for Immunoturbidimetric Assay, ELISA, Chemiluminescence Immunoassay and Other Assay Types for the Years 2015, 2025 & 2030
    • TABLE 122: Italy Recent Past, Current & Future Analysis for C-Reactive Protein Testing by End-Use - Hospitals, Laboratories, Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Italy Historic Review for C-Reactive Protein Testing by End-Use - Hospitals, Laboratories, Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 124: Italy 15-Year Perspective for C-Reactive Protein Testing by End-Use - Percentage Breakdown of Value Sales for Hospitals, Laboratories, Clinics and Other End-Uses for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • C-Reactive Protein Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 125: UK Recent Past, Current & Future Analysis for C-Reactive Protein Testing by Disease Type - Cardiovascular Diseases, Cancer, Rheumatoid Arthritis, Inflammatory Bowel Disease, Endometriosis, Lupus and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 126: UK Historic Review for C-Reactive Protein Testing by Disease Type - Cardiovascular Diseases, Cancer, Rheumatoid Arthritis, Inflammatory Bowel Disease, Endometriosis, Lupus and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 127: UK 15-Year Perspective for C-Reactive Protein Testing by Disease Type - Percentage Breakdown of Value Sales for Cardiovascular Diseases, Cancer, Rheumatoid Arthritis, Inflammatory Bowel Disease, Endometriosis, Lupus and Other Disease Types for the Years 2015, 2025 & 2030
    • TABLE 128: UK Recent Past, Current & Future Analysis for C-Reactive Protein Testing by Assay Type - Immunoturbidimetric Assay, ELISA, Chemiluminescence Immunoassay and Other Assay Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 129: UK Historic Review for C-Reactive Protein Testing by Assay Type - Immunoturbidimetric Assay, ELISA, Chemiluminescence Immunoassay and Other Assay Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 130: UK 15-Year Perspective for C-Reactive Protein Testing by Assay Type - Percentage Breakdown of Value Sales for Immunoturbidimetric Assay, ELISA, Chemiluminescence Immunoassay and Other Assay Types for the Years 2015, 2025 & 2030
    • TABLE 131: UK Recent Past, Current & Future Analysis for C-Reactive Protein Testing by End-Use - Hospitals, Laboratories, Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 132: UK Historic Review for C-Reactive Protein Testing by End-Use - Hospitals, Laboratories, Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 133: UK 15-Year Perspective for C-Reactive Protein Testing by End-Use - Percentage Breakdown of Value Sales for Hospitals, Laboratories, Clinics and Other End-Uses for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 134: Rest of Europe Recent Past, Current & Future Analysis for C-Reactive Protein Testing by Disease Type - Cardiovascular Diseases, Cancer, Rheumatoid Arthritis, Inflammatory Bowel Disease, Endometriosis, Lupus and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Rest of Europe Historic Review for C-Reactive Protein Testing by Disease Type - Cardiovascular Diseases, Cancer, Rheumatoid Arthritis, Inflammatory Bowel Disease, Endometriosis, Lupus and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 136: Rest of Europe 15-Year Perspective for C-Reactive Protein Testing by Disease Type - Percentage Breakdown of Value Sales for Cardiovascular Diseases, Cancer, Rheumatoid Arthritis, Inflammatory Bowel Disease, Endometriosis, Lupus and Other Disease Types for the Years 2015, 2025 & 2030
    • TABLE 137: Rest of Europe Recent Past, Current & Future Analysis for C-Reactive Protein Testing by Assay Type - Immunoturbidimetric Assay, ELISA, Chemiluminescence Immunoassay and Other Assay Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Rest of Europe Historic Review for C-Reactive Protein Testing by Assay Type - Immunoturbidimetric Assay, ELISA, Chemiluminescence Immunoassay and Other Assay Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 139: Rest of Europe 15-Year Perspective for C-Reactive Protein Testing by Assay Type - Percentage Breakdown of Value Sales for Immunoturbidimetric Assay, ELISA, Chemiluminescence Immunoassay and Other Assay Types for the Years 2015, 2025 & 2030
    • TABLE 140: Rest of Europe Recent Past, Current & Future Analysis for C-Reactive Protein Testing by End-Use - Hospitals, Laboratories, Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Rest of Europe Historic Review for C-Reactive Protein Testing by End-Use - Hospitals, Laboratories, Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 142: Rest of Europe 15-Year Perspective for C-Reactive Protein Testing by End-Use - Percentage Breakdown of Value Sales for Hospitals, Laboratories, Clinics and Other End-Uses for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • C-Reactive Protein Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 143: Asia-Pacific Recent Past, Current & Future Analysis for C-Reactive Protein Testing by Disease Type - Cardiovascular Diseases, Cancer, Rheumatoid Arthritis, Inflammatory Bowel Disease, Endometriosis, Lupus and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Asia-Pacific Historic Review for C-Reactive Protein Testing by Disease Type - Cardiovascular Diseases, Cancer, Rheumatoid Arthritis, Inflammatory Bowel Disease, Endometriosis, Lupus and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 145: Asia-Pacific 15-Year Perspective for C-Reactive Protein Testing by Disease Type - Percentage Breakdown of Value Sales for Cardiovascular Diseases, Cancer, Rheumatoid Arthritis, Inflammatory Bowel Disease, Endometriosis, Lupus and Other Disease Types for the Years 2015, 2025 & 2030
    • TABLE 146: Asia-Pacific Recent Past, Current & Future Analysis for C-Reactive Protein Testing by Assay Type - Immunoturbidimetric Assay, ELISA, Chemiluminescence Immunoassay and Other Assay Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Asia-Pacific Historic Review for C-Reactive Protein Testing by Assay Type - Immunoturbidimetric Assay, ELISA, Chemiluminescence Immunoassay and Other Assay Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 148: Asia-Pacific 15-Year Perspective for C-Reactive Protein Testing by Assay Type - Percentage Breakdown of Value Sales for Immunoturbidimetric Assay, ELISA, Chemiluminescence Immunoassay and Other Assay Types for the Years 2015, 2025 & 2030
    • TABLE 149: Asia-Pacific Recent Past, Current & Future Analysis for C-Reactive Protein Testing by End-Use - Hospitals, Laboratories, Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Asia-Pacific Historic Review for C-Reactive Protein Testing by End-Use - Hospitals, Laboratories, Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 151: Asia-Pacific 15-Year Perspective for C-Reactive Protein Testing by End-Use - Percentage Breakdown of Value Sales for Hospitals, Laboratories, Clinics and Other End-Uses for the Years 2015, 2025 & 2030
  • REST OF WORLD
    • TABLE 152: Rest of World Recent Past, Current & Future Analysis for C-Reactive Protein Testing by Disease Type - Cardiovascular Diseases, Cancer, Rheumatoid Arthritis, Inflammatory Bowel Disease, Endometriosis, Lupus and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Rest of World Historic Review for C-Reactive Protein Testing by Disease Type - Cardiovascular Diseases, Cancer, Rheumatoid Arthritis, Inflammatory Bowel Disease, Endometriosis, Lupus and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 154: Rest of World 15-Year Perspective for C-Reactive Protein Testing by Disease Type - Percentage Breakdown of Value Sales for Cardiovascular Diseases, Cancer, Rheumatoid Arthritis, Inflammatory Bowel Disease, Endometriosis, Lupus and Other Disease Types for the Years 2015, 2025 & 2030
    • TABLE 155: Rest of World Recent Past, Current & Future Analysis for C-Reactive Protein Testing by Assay Type - Immunoturbidimetric Assay, ELISA, Chemiluminescence Immunoassay and Other Assay Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Rest of World Historic Review for C-Reactive Protein Testing by Assay Type - Immunoturbidimetric Assay, ELISA, Chemiluminescence Immunoassay and Other Assay Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 157: Rest of World 15-Year Perspective for C-Reactive Protein Testing by Assay Type - Percentage Breakdown of Value Sales for Immunoturbidimetric Assay, ELISA, Chemiluminescence Immunoassay and Other Assay Types for the Years 2015, 2025 & 2030
    • TABLE 158: Rest of World Recent Past, Current & Future Analysis for C-Reactive Protein Testing by End-Use - Hospitals, Laboratories, Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Rest of World Historic Review for C-Reactive Protein Testing by End-Use - Hospitals, Laboratories, Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 160: Rest of World 15-Year Perspective for C-Reactive Protein Testing by End-Use - Percentage Breakdown of Value Sales for Hospitals, Laboratories, Clinics and Other End-Uses for the Years 2015, 2025 & 2030

IV. COMPETITION

Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!